JP7534291B2 - ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法 - Google Patents

９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法 Download PDF

Info

Publication number
JP7534291B2
JP7534291B2 JP2021521085A JP2021521085A JP7534291B2 JP 7534291 B2 JP7534291 B2 JP 7534291B2 JP 2021521085 A JP2021521085 A JP 2021521085A JP 2021521085 A JP2021521085 A JP 2021521085A JP 7534291 B2 JP7534291 B2 JP 7534291B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
formula
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505146A5 (https=
JPWO2020082065A5 (https=
JP2022505146A (ja
Inventor
フランセスコ ジー． サリトゥロ，
マリア ヘスス ブランコ－ピヤド，
マーシャル リー モーニングスター，
ボイド エル． ハリソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2022505146A publication Critical patent/JP2022505146A/ja
Publication of JP2022505146A5 publication Critical patent/JP2022505146A5/ja
Publication of JPWO2020082065A5 publication Critical patent/JPWO2020082065A5/ja
Priority to JP2024075254A priority Critical patent/JP2024096347A/ja
Application granted granted Critical
Publication of JP7534291B2 publication Critical patent/JP7534291B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0007—Androstane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2021521085A 2018-10-19 2019-10-21 ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法 Active JP7534291B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024075254A JP2024096347A (ja) 2018-10-19 2024-05-07 ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748016P 2018-10-19 2018-10-19
US62/748,016 2018-10-19
PCT/US2019/057195 WO2020082065A1 (en) 2018-10-19 2019-10-21 9(11)-unsaturated neuroactive steroids and their methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024075254A Division JP2024096347A (ja) 2018-10-19 2024-05-07 ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法

Publications (4)

Publication Number Publication Date
JP2022505146A JP2022505146A (ja) 2022-01-14
JP2022505146A5 JP2022505146A5 (https=) 2022-10-31
JPWO2020082065A5 JPWO2020082065A5 (https=) 2022-10-31
JP7534291B2 true JP7534291B2 (ja) 2024-08-14

Family

ID=68468867

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521085A Active JP7534291B2 (ja) 2018-10-19 2019-10-21 ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法
JP2024075254A Pending JP2024096347A (ja) 2018-10-19 2024-05-07 ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024075254A Pending JP2024096347A (ja) 2018-10-19 2024-05-07 ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法

Country Status (13)

Country Link
US (2) US20210363175A1 (https=)
EP (2) EP3867261B1 (https=)
JP (2) JP7534291B2 (https=)
CN (1) CN113227114B (https=)
AR (1) AR116771A1 (https=)
AU (2) AU2019359899B2 (https=)
BR (1) BR112021007401A2 (https=)
CA (1) CA3116892A1 (https=)
DK (1) DK3867261T3 (https=)
ES (1) ES3039267T3 (https=)
MX (2) MX2021004452A (https=)
TW (1) TW202027754A (https=)
WO (1) WO2020082065A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061527A1 (en) 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
DE2526373C2 (de) * 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
JP2545522B2 (ja) * 1985-10-23 1996-10-23 アルコン・ラボラトーリーズ，インコーポレイテッド テトラヒドロ脈管形成抑制ステロイド
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061527A1 (en) 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use

Also Published As

Publication number Publication date
BR112021007401A2 (pt) 2021-08-03
AU2024220209A1 (en) 2024-10-17
US20210363175A1 (en) 2021-11-25
EP3867261A1 (en) 2021-08-25
EP3867261B1 (en) 2025-04-30
TW202027754A (zh) 2020-08-01
EP4606812A2 (en) 2025-08-27
JP2022505146A (ja) 2022-01-14
US20250136638A1 (en) 2025-05-01
AU2019359899B2 (en) 2024-07-04
ES3039267T3 (en) 2025-10-20
CA3116892A1 (en) 2020-04-23
WO2020082065A1 (en) 2020-04-23
CN113227114A (zh) 2021-08-06
MX2021004452A (es) 2021-08-11
AR116771A1 (es) 2021-06-09
AU2019359899A1 (en) 2021-05-20
CN113227114B (zh) 2026-01-27
EP4606812A3 (en) 2025-10-15
MX2024014845A (es) 2025-01-09
JP2024096347A (ja) 2024-07-12
DK3867261T3 (da) 2025-08-18

Similar Documents

Publication Publication Date Title
JP7611186B2 (ja) Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法
JP7510461B2 (ja) Ｃｎｓ障害を処置するための組成物および方法
JP7821842B2 (ja) Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法
JP7670754B2 (ja) Ｃｎｓ障害の処置のための組成物および方法
JP7534291B2 (ja) ９（１１）－不飽和神経刺激性ステロイド及びそれらの使用方法
JP7671244B2 (ja) Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド
EP3250210B1 (en) Compositions and methods for treating cns disorders
JP7692830B2 (ja) ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物
JP2018505898A (ja) 神経刺激性ステロイド、組成物、およびその使用
JP2025060984A (ja) Ｃｎｓ障害を治療するための組成物及び方法
HK40130819A (en) 9(11)-unsaturated neuroactive steroids and their methods of use
HK40106568A (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
HK40059498A (en) 9(11)-unsaturated neuroactive steroids and their methods of use
HK40059498B (en) 9(11)-unsaturated neuroactive steroids and their methods of use
HK40059417A (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
HK40059417B (en) Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
BR122024013785A2 (pt) Compostos esteroides neuroativos, composição farmacêutica e seus usos
HK40008786A (en) C7, c12, and c16 substituted neuroactive steroids and their methods of use
HK40008786B (en) C7, c12, and c16 substituted neuroactive steroids and their methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240801

R150 Certificate of patent or registration of utility model

Ref document number: 7534291

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350